1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?

 
• By Alaric DeArment

AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.

AZ Cambridge campus
AstraZeneca - along with Pfizer and J&J - presented Phase III PARP inhibitor data in first-line prostate cancer at ASCO GU • Source: Shutterstock

Data from three Phase III studies presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) give a preview of what is set to become a highly competitive field for PARP inhibitors combined with anti-androgen drugs in first-line metastatic castration-resistant prostate cancer (mCRPC). With its more established position in the field, AstraZeneca PLC’s Lynparza (olaparib) may retain a competitive edge, but the space looks likely to become a three-way competition between it, Pfizer Inc.’s Talzenna (talazoparib) and Johnson & Johnson/GSK plc’s Zejula (niraparib).

ASCO GU included presentations on 16 February from three Phase III studies in particular: the PROpel trial of Lynparza combined...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

More from Therapy Areas

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.